4,103 results match your criteria Alopecia Areata


The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review

J Drugs Dermatol 2019 Feb;18(2):155-160

Introduction: Topical minoxidil is the first-line therapy for treating both male and female androgenetic alopecia. Currently there are no comprehensive reviews on the clinical efficacy of minoxidil on hair loss. Method: A literature search was conducted to identify clinically relevant studies regarding the efficacy of topical minoxidil for human subjects for hair loss. Read More

View Article

Download full-text PDF

Source
February 2019

Differential expression patterns of specific long noncoding RNAs and competing endogenous RNA network in alopecia areata.

J Cell Biochem 2019 Feb 20. Epub 2019 Feb 20.

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.

Background: Long noncoding RNAs (lncRNAs) regulate gene expression by acting with microRNAs (miRNAs) and indirectly interact with messenger RNA (mRNAs). However, the roles of specific lncRNA and its related competing endogenous RNAs (ceRNA) network in alopecia areata (AA) are not fully understood.

Methods: The blood lncRNA profiles were obtained by microarray from 10 samples, including five alopecia areata samples and five normal samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.28365DOI Listing
February 2019

Nuchal Nevus Flammeus and Alopecia Areata: When Size Matters.

Int J Trichology 2018 Nov-Dec;10(6):275-277

Department of Dermatology, Hospital Clínic de Barcelona, Barcelona, Spain.

Introduction: Alopecia areata (AA) is a high-prevalence immuno-mediated hair loss disorder. Extra follicular affections, including nail and ocular abnormalities, are classically related to a worse prognosis of the disease, and previous studies have suggested that the presence of a persistent nuchal nevus flammeus (NNF) also indicates a greater severity and duration of the disease. The association between AA and persistent NNF was first described by Hatzis et al in 1988, who demonstrated that the relation was statistically evident and not due to a simple observer bias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijt.ijt_82_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369638PMC
February 2019

The Impact of Alopecia Areata on Sexual Quality of Life.

Int J Trichology 2018 Nov-Dec;10(6):271-274

Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.

Background: Alopecia areata (AA) is an autoimmune disease characterized by patches of hair loss that can cause decreased quality of life. This study evaluates the sexual quality of life for patients with AA.

Methods: We surveyed patients in the National Alopecia Areata Foundation patient registry using an online version of the validated Sexual Quality of Life for Females (SQOL-F) and Sexual Quality of Life for Males (SQOL-M) questionnaires. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijt.ijt_93_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369646PMC
February 2019

Evaluation of Association of Vitamin D in Alopecia Areata: A Case-control Study of 100 Patients in a Tertiary Rural Hospital of Southern India.

Indian Dermatol Online J 2019 Jan-Feb;10(1):45-49

Department of Dermatology, Raja Rajeswari Medical College and Hospital, Kambipura, Mysore Road, Bangalore, Karnataka, India.

Background: Alopecia areata is a common autoimmune disorder which is characterized by non-scarring hair loss. Vitamin D plays an important role in immune regulation, cell growth, differentiation, and maintenance of hair cycle.

Aims And Objectives: (1) To evaluate serum vitamin D levels in alopecia areata. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_84_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362755PMC
February 2019

Clinico-Epidemiological Profile of Patients with Vitiligo: A Retrospective Study from a Tertiary Care Center of North India.

Indian Dermatol Online J 2019 Jan-Feb;10(1):38-44

Department of Dermatology, Venereology and Leprosy, Dr. R. P. Govt. Medical College, Kangra (Tanda), Himachal Pradesh, India.

Background: We studied clinico-epidemiological features of 945 patients with vitiligo with an objective to delineate epidemiological and clinical aspects of vitiligo from this part of the country.

Materials And Methods: The medical records of patients with vitiligo attending outpatient clinic over a 5-year period from January 2013 to December 2017 were analyzed retrospectively for this descriptive, observational study.

Results: There were 449 men and 496 women (m:f 1:1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_124_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362747PMC
February 2019

JAK inhibitors for alopecia areata: a systematic review and meta-analysis.

J Eur Acad Dermatol Venereol 2019 Feb 14. Epub 2019 Feb 14.

Department of Dermatology, Liverpool Hospital, Sydney, Australia.

Background: There have been a number of case reports and small clinical trials reporting promising outcomes of JAK inhibitors tofacitinib, ruxolitinib, and baracitinib for alopecia areata (AA). The majority of the literature to date is based on small volume data, with a lack of definitive evidence or guidelines.

Objective: To determine the expected response of AA to JAK inhibitor therapy, and factors which influence response and recurrence rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15489DOI Listing
February 2019
1 Read

Ischemic modified albumin as a new biomarker in predicting oxidative stress in alopecia areata

Turk J Med Sci 2019 Feb 11;49(1):129-138. Epub 2019 Feb 11.

Background/aim: Results show that oxidative stress is a pathophysiologic factor for alopecia areata (AA); however, the markers used can be confounding. Thus, we aimed to investigate the role of oxidative stress in the pathogenesis of AA through an evaluation of ischemia-modified albumin (IMA); other markers of the oxidant/antioxidant system, such as SOD, CAT, GSH-ST, and MDA; and contributing clinical risk factors.

Materials And Methods: The usefulness of IMA as a new marker for oxidative stress was compared with that of other markers and evaluated in patients with AA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3906/sag-1708-35DOI Listing
February 2019

Trichoscopy features of trichotillomania.

Pediatr Dermatol 2019 Feb 11. Epub 2019 Feb 11.

Department of Dermatology, Hospital Clinico Universitario, Valencia, Spain.

Trichotillomania is a form of traction alopecia resulting from repetitive and compulsive hair pulling and plucking. Trichotillomania and patchy alopecia areata may have similar clinical and dermoscopic features in some cases. On trichoscopic examination, the presence of black dots, coiled or hook hair, shafts of varying lengths with fraying or split ends (trichoptilosis), and an absence of exclamation mark hairs and yellow dots are suggestive of trichotillomania. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13756DOI Listing
February 2019
2 Reads

The Effectiveness of Oral Mini-Pulse Methylprednisolonein - the Treatment of Alopecia Areata in Vietnam.

Open Access Maced J Med Sci 2019 Jan 29;7(2):291-292. Epub 2019 Jan 29.

University of Rome G. Marconi, Rome, Italy.

Background: Systemic corticosteroid is used to treat alopecia areata, but it is associated with side effects. Mini-pulse therapy is thought to be effective but able to reduce side effects.

Aim: The study aimed to evaluate the effectiveness of oral mini-pulse methylprednisolone in the treatment of alopecia areata. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364712PMC
January 2019

Efficacy and Safety of Methotrexate in Combination with Mini Pulse Doses of Methylprednisolone in Severe Alopecia Areata. The Vietnamese Experience.

Open Access Maced J Med Sci 2019 Jan 23;7(2):200-203. Epub 2019 Jan 23.

University of Rome G. Marconi, Rome, Italy.

Background: Treatment of severe alopecia areata remains very difficult, especially in alopecia areata totalis and alopecia areata universalis. Methotrexate is known to be effective in the treatment of severe and chronic autoimmune disorders.

Objective: To assess the effectiveness and safety of MTX in combination with mini pulse dose of methylprednisolone in the treatment of severe alopecia areata. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364718PMC
January 2019

A Study of the Histopathological Features of Alopecias on Transverse Sections of Scalp Biopsies.

Indian J Dermatol 2019 Jan-Feb;64(1):47-54

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

Background: Transverse sections of scalp biopsies are performed for the assessment of alopecias and are considered advantageous over vertical sections.

Aim: The aim was to study the histopathological features of alopecias on transverse sections of scalp biopsies.

Methods: It was a descriptive study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_477_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340243PMC
February 2019
2 Reads

Assessment of Metabolic Profile and Ischemia-modified Albumin Level in Patients with Alopecia Areata: A Case-Control Study.

Indian J Dermatol 2019 Jan-Feb;64(1):12-18

Department of Medical Biochemistry, Ankara Numune Training and Research Hospital, Ankara, Turkey.

Background: Alopecia areata (AA) is an autoimmune-mediated hair follicle disorder. In the literature, there is no study evaluating metabolic syndrome and levels of ischemia-modified albumin (IMA) which is proposed as an oxidative stress biomarker in patients with AA.

Aims: The aim was to investigate the presence of metabolic syndrome and the levels of IMA, small dense low-density lipoprotein (sd-LDL), and visfatin levels in AA patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_238_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340238PMC
February 2019
2 Reads

Alopecia Areata Different View; Heavy Metals.

Indian J Dermatol 2019 Jan-Feb;64(1):7-11

Department of Dermatology, Yuzuncu Yil University, Faculty of Medicine, Van, Turkey.

Background: Alopecia areata (AA) is a noncicatricial alopecia affecting any hair-bearing area. Although AA is considered to be an autoimmune disease, oxidative stress has been shown to be an important factor in the etiology of AA. Trace elements are highly essential for humans since they form the building blocks of large molecules, function as the cofactors of enzymes, and have some key biological functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_137_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340228PMC
February 2019
2 Reads

Pathogenesis of Alopecia Areata Based on Bioinformatics Analysis.

Indian J Dermatol 2019 Jan-Feb;64(1):1-6

Department of Toxicology, School of Public Health, Shaanxi University of Chinese Medicine, Xi'an, China.

Background: Alopecia areata (AA) describes a sudden localized patchy alopecia. The cause of AA is not completely clear and its incidence may be related to genetic, autoimmune, and environmental factors.

Aim: To explore the possible mechanisms of AA and to provide a basis for the early diagnosis and treatment of AA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_68_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340232PMC
February 2019
1 Read

Agreement Between Self-reported and Dermatologists' Diagnosis for Alopecia Areata and Atopic Dermatitis: A Bi-centric Prospective Study.

Acta Derm Venereol 2019 Feb 6. Epub 2019 Feb 6.

Department of Dermatology, University Hospital, FR-25000 Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3135DOI Listing
February 2019

JAK inhibitors and alopecia areata.

Lancet 2019 01;393(10169):318-319

Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; Centre for Dermatology Research, University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01406736183298
Publisher Site
http://dx.doi.org/10.1016/S0140-6736(18)32987-8DOI Listing
January 2019
2 Reads

Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients.

Dermatol Ther 2019 Jan 28:e12844. Epub 2019 Jan 28.

Department of Dermatology, Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12844DOI Listing
January 2019
2 Reads

Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.

Prostate Cancer Prostatic Dis 2019 Jan 28. Epub 2019 Jan 28.

Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.

Background: Androgen deprivation therapy (ADT) has been a mainstay of treatment for advanced prostate cancer (PCa), but limited studies have been performed to investigate the association between ADT and autoimmune diseases.

Methods: We conducted a population-based nationwide cohort study of 17,168 patients newly diagnosed with PCa between 1996 and 2013 using the National Health Insurance Research Database (NHIRD) of Taiwan. Cox proportional hazards models with 1:1 propensity score-matched analysis were used to investigate the association between ADT use and the risk of autoimmune diseases. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-019-0130-9
Publisher Site
http://dx.doi.org/10.1038/s41391-019-0130-9DOI Listing
January 2019
6 Reads

The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.

J Cutan Med Surg 2019 Jan 28:1203475418824079. Epub 2019 Jan 28.

1 SKiN Centre for Dermatology, Peterborough, ON, Canada.

Alopecia areata (AA) is a chronic, immune-mediated disorder that targets hair follicle epithelium, thereby restricting hair growth in localized patches. Although several therapies for AA have been tested, responses with traditional therapies have been limited. In recent years, numerous reports have been published of patients with AA responding to Janus kinase (JAK) inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475418824079DOI Listing
January 2019
1 Read

Rule of thumb: a simple tool to estimate 1% scalp surface area.

J Am Acad Dermatol 2019 Jan 22. Epub 2019 Jan 22.

Department of Dermatology, Yale University School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.01.022DOI Listing
January 2019

Role of family history in patchy alopecia areata.

Dermatol Online J 2018 Oct 15;24(10). Epub 2018 Oct 15.

Case Western Reserve University School of Medicine, Cleveland, Ohio.

Background: Family history of alopecia areata has been associated with more severe clinical presentations, but its specific prognostic implications in patchy alopecia remains unclear.

Objective: To evaluate the relationship of family history of alopecia areata with demographics, triggers, comorbidities, disease course, and relapse rate in patchy alopecia.

Methods: The medical records of 256 patients seen over a 17-year period was examined. Read More

View Article

Download full-text PDF

Source
October 2018
1 Read

PD-1 inhibitor induced alopecia areata.

Dermatol Online J 2018 Dec 15;24(12). Epub 2018 Dec 15.

Division of Cutaneous Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, Colorado.

Immune checkpoint modulators are becoming more prevalent in clinical use for the treatment of metastatic melanoma and other malignancies. These drugs, including programmed death 1 (PD-1) inhibitors, have a high incidence of immune adverse events, including cutaneous manifestations. Alopecia is a known side effect with these drugs, but previous reports describe chemotherapy-induced alopecia. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Alopecia areata in Tunisia: epidemio-clinical aspects and comorbid conditions. A prospective study of 204 cases.

Int J Dermatol 2019 Jan 24. Epub 2019 Jan 24.

Dermatology Department, Farhat Hached University Hospital, Sousse, Tunisia.

Background: Alopecia areata (AA) is an autoimmune condition that usually presents as patchy, nonscarring hair loss. Autoimmune disorders and atopy are reported as comorbid conditions. We aimed to investigate the demographics, clinical characteristics, and associations of AA in Tunisian patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14381DOI Listing
January 2019
2 Reads

Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab.

JAAD Case Rep 2019 Feb 12;5(2):116-117. Epub 2019 Jan 12.

Department of Dermatology, University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525126183033
Publisher Site
http://dx.doi.org/10.1016/j.jdcr.2018.11.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330370PMC
February 2019
5 Reads

Tinea versicolor of the neck as side effect of topical steroids for alopecia areata.

J Dermatolog Treat 2019 Jan 22:1-3. Epub 2019 Jan 22.

a Department of Experimental, Diagnostic and Specialty Medicine, Division of Dermatology , University of Bologna , Bologna , Italy.

Background: Treatment of alopecia areata (AA) involves use of high potency topical corticosteroids under occlusion that, even very effective, can lead to several adverse effects.

Objective: We report 10 cases of patients with AA that, after using high potency topical corticosteroids, have developed tinea versicolor of the neck area.

Methods: Ten patients with AA, aged 18-38 years, were prescribed with clobetasone propionate 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1573308DOI Listing
January 2019
2 Reads

Jarilla-Coffea extract: a natural cosmetic product that improves eyelash and eyebrow growth in women.

Clin Cosmet Investig Dermatol 2019 9;12:47-55. Epub 2019 Jan 9.

Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Department of Pharmacology, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina,

Purpose: A combination of extracts, from two plant species, ie, and (Jarilla) (ECOHAIR) is being successfully used in Argentina as a cosmetic for hair recovery in androgenic and areata alopecia, and for eyelash and eyebrow growth. The objectives of this prospective study were to evaluate the capacity of Jarilla-Coffea extract gel of improving hair growth in relation to thickness, appearance of new hair, and hair length in comparison with a placebo in premenopausal and postmenopausal volunteers and to identify possible signs of ocular adverse local reactions related to the application of the gel.

Volunteers And Methods: An open-label, placebo-controlled, prospective study was performed in healthy premenopausal and postmenopausal women during a daily administration period of 2 months (eyebrow growth) and 3 months (eyelash growth). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CCID.S182497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330964PMC
January 2019
2 Reads

ALLERGIC CONTACT DERMATITIS PROBABLY DUE TO LATANOPROST DURING TREATMENT FOR ALOPECIA AREATA.

Contact Dermatitis 2019 Jan 21. Epub 2019 Jan 21.

Department of Health Sciences, University Magna Graecia, Catanzaro, Italy.

Latanoprost is a phenyl-substituted analogue of prostaglandin F2α used to treat glaucoma (1). Recently, it has been shown to stimulate eyelash hypertrichosis and therefore it has been proposed as a possible treatment for alopecia (2). Despite the extensive use of the drug in ophthalmology, allergic contact dermatitis (ACD) due to latanoprost has rarely been reported in glaucoma patients (3-6). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cod.13228DOI Listing
January 2019
3 Reads

Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata.

JAMA Dermatol 2019 Jan 16. Epub 2019 Jan 16.

Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Importance: Alopecia areata (AA) is an autoimmune disease characterized by hair loss that can impose a substantial psychological burden on patients, including major depressive disorder (MDD), yet many patients report mental health symptoms prior to the onset of AA. As such, there may be an association between MDD and AA that acts in both directions.

Objective: To assess the bidirectional association between MDD and AA. Read More

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2018.4398DOI Listing
January 2019
6 Reads

Trichoscopy of Dark Scalp.

Skin Appendage Disord 2018 Nov 18;5(1):1-8. Epub 2018 Jul 18.

Department of Dermatology, University of Miami, Miami, Florida, USA.

Trichoscopy (dermoscopy of the hair and scalp) is a technique that improves diagnostic accuracy and follow-up with hair and scalp disorders. Although several studies of trichoscopy have been made in Caucasian and Asian populations, little has been published regarding trichoscopy findings in skin of color, despite the great prevalence of hair diseases in populations with this kind of skin. The aim of this review was to describe the trichoscopic features of normal scalp and of hair disorders in patients with dark skin phototypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488885DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323385PMC
November 2018
3 Reads

New drugs under investigation for the treatment of alopecias.

Expert Opin Investig Drugs 2019 Mar 22;28(3):275-284. Epub 2019 Jan 22.

b Department of Dermatology and Cutaneous Surgery , University of Miami Miller School of Medicine , Miami , FL , USA.

Introduction: Alopecia is a very common complaint in medical practice, which usually has a large psychological impact in patients. Treatment of alopecia is often difficult and frustrating for patients and clinicians owing to the slow growth rate of the hair, long treatment terms, limited efficacy, and possible adverse side effects. Areas covered: This paper reviews the new and emerging treatments for two of the most common forms of alopecia, known as androgenetic alopecia and alopecia areata. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1568989DOI Listing

Dickkopf-1 Expression in Androgenetic Alopecia and Alopecia Areata in Male Patients.

Am J Dermatopathol 2019 Feb;41(2):122-127

Dermatology and Venereology and.

Background: Androgenetic alopecia (AGA) results from shortening of the anagen phase of the hair cycle and, subsequently, miniaturization of hair follicles. Alopecia areata (AA) is a disease of autoimmunity where T cells attack anagen hair follicles and shows multifactorial etiology. Dickkopf-1 (DKK-1) is a gene that is responsible for transformation of anagen to catagen, which suggests that it is involved in development of both diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001266DOI Listing
February 2019
6 Reads

Non-scarring Alopecias in Iranian Patients: A Histopathological Study With Hair Counts.

Iran J Pathol 2018 12;13(3):317-324. Epub 2018 Sep 12.

Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Background And Objective: Non-scarring alopecia is a challenge in the diagnosis and treatment, rarely studied in Asian countries.The current study aimed at evaluating histopathological features including hair count of different subtypes of non-scarring alopecia in Iranian patients.

Methods: The current study was conducted on 114 cases diagnosed with non-scarring alopecia in Molecular Dermatology Research Center and Pathology Department of Shiraz University of Medical Sciences, Shiraz, Iran. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322526PMC
September 2018
6 Reads

Alopecia Areata and Thyroid Dysfunction Association- A Study from Eastern Nepal.

Kathmandu Univ Med J (KUMJ) 2018 Apr-Jun;16(62):161-165

Department of Biochemistry, BP Koirala Institute of Health Sciences, Dharan, Nepal.

Background Alopecia areata (AA) is one of the non-scarring alopecia. Its etiology has not been well established till date. The most convincing hypothesis is autoimmune process for its causation. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: a prospective, cross-sectional study.

J Am Acad Dermatol 2019 Jan 8. Epub 2019 Jan 8.

Division of Pediatrics, Section of Dermatology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address:

Background: Caregiver-oriented quality of life research (QoL) in alopecia areata is limited. No study has used a parent-tailored survey to examine the relationship between QoL and severity of alopecia as measured by SALT scores.

Objectives: This is a prospective study that describes QoL in parents of pediatric patients with all subtypes of alopecia areata and investigates the relationship between QoL and severity of disease, duration of disease, and age of patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622193005
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2018.12.051DOI Listing
January 2019
9 Reads

Tofacitinib therapy for children with severe alopecia areata.

J Am Acad Dermatol 2019 Jan 7. Epub 2019 Jan 7.

Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Dermatology, National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.12.041DOI Listing
January 2019
1 Read

White hair in alopecia areata: Clinical forms and proposed physiopathological mechanisms.

J Am Acad Dermatol 2019 Jan 7. Epub 2019 Jan 7.

Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida.

Alopecia areata is a common form of non-scaring type of hair loss. It is believed to be a consequence of an immune-mediated stimulus, probably involving autoreactive T-cells against antigens present in the hair follicle. The exact antigen is still unknown; however, some authors have proposed that melanogenesis-associated molecules might trigger autoimmunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.12.047DOI Listing
January 2019
1 Read

Use of JAK inhibitors in treatment of Alopecia areata.

Authors:
Aila Malik

J Pak Med Assoc 2019 Jan;69(1):146

CMH Lahore Medical College, Lahore, Pakistan.

View Article

Download full-text PDF

Source
January 2019

Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens.

Postepy Dermatol Alergol 2018 Dec 8;35(6):577-581. Epub 2018 Nov 8.

Department of Dermatology, Venereology and Allergology, Faculty of Medicine and Dentistry, Wroclaw Medical University, Wroclaw, Poland.

Introduction: Alopecia areata (AA) is a skin disease of unclear etiology. In AA, topical immunotherapy with diphenylcyclopropenone (DPCP) is considered the most effective treatment; however, the most common therapies give unsatisfactory results.

Aim: To assess the efficacy of a topical application of a solution of DPCP based on the intensity, duration and number of exacerbations of AA and to compare the efficacy of two treatment regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2018.77608DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320486PMC
December 2018
2 Reads

Investigation of oxidative stress in patients with alopecia areata by measuring the levels of malondialdehyde and ceruloplasmin in the blood.

Postepy Dermatol Alergol 2018 Dec 8;35(6):572-576. Epub 2018 Nov 8.

Department of Pathobiochemistry and Clinical Chemistry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.

Introduction: Alopecia areata (AA) is a chronic, inflammatory and autoimmune disease, presenting with non-scarring hair loss. Although the precise etiopathogenesis of AA remains unknown, oxidative stress is thought to play a role.

Aim: To investigate the role of oxidative stress in AA by measuring the levels of plasma and erythrocyte malondialdehyde (MDA) and the ceruloplasmin (CER) in serum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pdia.2017.68047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320487PMC
December 2018
1 Read

A Comment on JAK Inhibitors for Treatment of Alopecia Areata.

Int J Trichology 2018 Sep-Oct;10(5):193-197

Department of Dermatology of the Fluminense Federal University, Antonio Pedro University Hospital, Niteroi, Brazil.

A meta-analysis of published trials on the treatment of alopecia areata (AA) came to the conclusion that most have been reported poorly and so small that any important clinical benefits are inconclusive, and considering the possibility of spontaneous remission, especially for those in the early stages of the disease, the options of not being treated or depending on individual preference, and of wearing a wig may be alternative ways of dealing with the condition. And yet, from clinical practice, we know that depending on patient age, surface area, disease duration, and comorbidities an empiric treatment algorithm can be designed that is successful in a significant proportion of patients. More recently, it has been suggested that Janus kinase (JAK) inhibitors may represent the drug of choice for AA, based on robust scientific background and preliminary clinical study results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijt.ijt_62_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290291PMC
January 2019
1 Read

The Efficacy of Platelet-Rich Plasma in the Field of Hair Restoration and Facial Aesthetics-A Systematic Review and Meta-analysis.

J Cutan Med Surg 2019 Jan 4:1203475418818073. Epub 2019 Jan 4.

2 Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Canada.

As a promising alternative to traditional treatment, platelet-rich plasma (PRP) is being used to encourage hair growth through the release of growth factors and cytokines. In addition to hair restoration, PRP's multifactorial capabilities can also be used to treat aging skin, facial scarring, and acne. The purpose of this review is to critically examine the success of PRP in the field of dermatology, with specific attention to the role of PRP in hair restoration. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1203475418818073
Publisher Site
http://dx.doi.org/10.1177/1203475418818073DOI Listing
January 2019
2 Reads

Off-Label Use of Topical Minoxidil in Alopecia: A Review.

Am J Clin Dermatol 2019 Jan 2. Epub 2019 Jan 2.

Department of Dermatology, Northwestern University, 676 N St Clair St, Suite 1600, Chicago, IL, 60611, USA.

Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia. It was approved by the United States Food and Drug Administration for the treatment of androgenetic alopecia in 1988. Since its approval, minoxidil has been used off-label for the treatment of many other types of alopecia, with minimal formal evidence of efficacy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0409-y
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0409-yDOI Listing
January 2019
6 Reads

[What's new in dermatological treatment?]

Authors:
V Descamps

Ann Dermatol Venereol 2018 Dec;145 Suppl 7:VIIS47-VIIS55

Service de dermatologie, Hôpital Bichat, université Paris 7, Paris, France. Electronic address:

The therapeutic revolution in the management of inflammatory dermatoses is under way. The therapeutic arsenal is expanding in the field of psoriasis, including biologics (TNF blockers, anti-IL12/IL23, anti-IL17, and anti-IL23 antibodies), new small molecules (tyrosine kinase inhibitor), and a new biologic for generalized pustular psoriasis (anti-IL36 receptor). New biologics will be soon available in the field of atopic dermatitis in addition to anti-IL4/IL13 antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0151-9638(18)31289-4DOI Listing
December 2018
8 Reads

Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases.

J Allergy Clin Immunol 2018 Dec 18. Epub 2018 Dec 18.

Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Background: Peripheral blood skin-homing/cutaneous lymphocyte antigen (CLA) T cells emerge as biomarkers of cutaneous immune activation in patients with inflammatory skin diseases (atopic dermatitis [AD] and alopecia areata [AA]). However, blood phenotyping across these subsets is not yet available in patients with vitiligo.

Objective: We sought to measure cytokine production by circulating skin-homing (CLA) versus systemic (CLA) "polar" CD4/CD8 ratio and activated T-cell subsets in patients with vitiligo compared with patients with AA, AD, or psoriasis and control subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2018.11.031DOI Listing
December 2018
5 Reads

Case of alemtuzumab-related alopecia areata management in MS.

Neurol Neuroimmunol Neuroinflamm 2019 Jan 19;6(1):e516. Epub 2018 Oct 19.

Department of Medicine (Neurology), University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000516DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278852PMC
January 2019

Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.

Dermatology 2018 Dec 19:1-7. Epub 2018 Dec 19.

Department of Dermatology, Farwaniya Hospital, Farwaniya, Kuwait.

Background: Alopecia areata (AA) is a common autoimmune disorder characterized by patchy hair loss. There are many treatments available for AA. However, treatments of severe forms of AA are not satisfactory. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494613DOI Listing
December 2018
3 Reads

Analysis of finger vein variety in patients with various diseases using vein authentication technology.

J Biophotonics 2018 Dec 18:e201800354. Epub 2018 Dec 18.

Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

In finger vein authentication technology, near-infrared rays penetrate the finger and are absorbed by the hemoglobin in blood. The veins appear as dark areas. The finger vein pattern images of patients with various diseases were acquired; a new evaluation method applying image processing technique ("E value") was developed, and it was examined whether the patterns have any characteristics differentiating them from those of healthy volunteers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbio.201800354DOI Listing
December 2018
2 Reads